Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$642.23M
EBITDA Margin
-266.60%
TTM Avg
-229.77%
3Y Avg
-154.97%
5Y Avg
-121.91%
Market Cap
$625.84M
EBITDA Margin
-4381.82%
TTM Avg
-5481.88%
3Y Avg
-5481.88%
5Y Avg
-3660.27%
Market Cap
$670.50M
EBITDA Margin
18.82%
TTM Avg
18.71%
3Y Avg
11.51%
5Y Avg
4.96%
Market Cap
$675.75M
EBITDA Margin
-178.29%
TTM Avg
-244867.52%
3Y Avg
-123424.79%
5Y Avg
-82415.31%
Market Cap
$610.22M
EBITDA Margin
-5.39%
TTM Avg
-5.12%
3Y Avg
-17.61%
5Y Avg
-12.23%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | $644.25M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $642.23M | -266.60% | -229.77% | -154.97% | -121.91% |
| Climb Bio, Inc. (CLYM)vs › | $637.34M | N/A | N/A | N/A | N/A |
| Prime Medicine, Inc. (PRME)vs › | $625.84M | -4381.82% | -5481.88% | -5481.88% | -3660.27% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $640.87M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $670.50M | 18.82% | 18.71% | 11.51% | 4.96% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.75M | -178.29% | -244867.52% | -123424.79% | -82415.31% |
| AngioDynamics, Inc. (ANGO)vs › | $610.22M | -5.39% | -5.12% | -17.61% | -12.23% |
| Annexon, Inc. (ANNX)vs › | $680.77M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $682.44M | -30265.74% | -30265.74% | -29547.55% | -23057.25% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
